- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02620384
Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study. (MELT-HF)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Heart failure is a major source of morbidity, mortality and growing public health cost. In US, the number of congestive heart failure patients is more than 4 million with more than 550,000 new annually reported cases. The annual cost of heart failure management exceeds 35 billion dollars per year.The heart failure readmissions and average length of hospital stay cost approximately $11,000 per patient.
Loop diuretics are used alone in the majority of cases to promote diuresis. An association of increased creatinine and increased risk of renal dysfunction, the cardiorenal syndrome, in the face of high dose loop diuretics has raised questions regarding the safety and toxicity of high dose loop diuretics. While the dose of diuretics is ubiquitous, little data exists to guide their use and many clinicians are uncertain as to when and how to initiate and limit therapy.
Prospective randomized data on large number of decompensated heart failure patients receiving metolazone in addition to standard therapy is scarce and needs further definitive evaluation in terms of clinical outcomes and safety. In many cases, a "stepped approach" with oral loop diuretics advancing to intravenous and finally combination high dose diuretics is employed.
Primary endpoint: Total urinary output and negative fluid balance in millilitres (ml) at 48 hours following first dose of intravenous diuretic.
Secondary endpoints:
- Change in weight from admission to day 2.
- Degree of improvement in dyspnea at 6,12, 24,36, and 48 hours assessed with Modified Borg Scale (1-10)
- All cause mortality at 30 days.
This is a single center study of at least 200 patients who are admitted to Aultman Hospital with clinical decompensated congestive heart failure ( NYHA III-IV). It is a double blinded randomized placebo- controlled pilot study of the addition of 5 mg of metolazone per day for 2 days compared to placebo in patients admitted with acute decompensated heart failure. We will compare a strategy of early institution of metolazone with standard of care in patients admitted with decompensated heart failure and volume overload. All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician.
After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. Two additional doses of metolazone within 6 and 24 hours of administration of standard intravenous diuretics will be given to the treatment arm. Patients and physicians will be blinded to the administered drug (metolazone vs placebo).Drug will be distributed by pharmacy when a patient is consented and enrolled in the trial. Specific guidance/recommendations regarding diuretic therapy will be provided (documented in detail below) but will be at the discretion of the treating physician. We will collect data on demographics, co-morbidities, clinical presentations and outcomes with metolazone administration with patient follow up at one week (+3) and 30 (±7) days post discharge.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Ohio
-
Canton, Ohio, United States, 44710
- Aultman Health Foundation
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 years or older
- Current hospitalization for chronic congestive heart failure with admission up to 48 hours prior to inclusion.
- Chronic heart failure will be defined as requiring treatment for a minimum of 30 days prior to current admission, NYHA Class III or IV at the time of hospitalization, and left ventricular ejection fraction less than 40% within one year or evidence of heart failure with preserved ejection fraction and evidence of diastolic dysfunction on echocardiogram.
- Admitted with clinical decompensated heart failure based on history, physical exam, and parameters indicating extracellular volume expansion such as including JVP ≥ 8 cm of water and 1+ or greater peripheral edema
- Is able to be dosed with study medication within six (6) hours of first dose of IV diuretics
Exclusion Criteria:
- Baseline severe hypotension (Mean arterial pressure < 55 mm Hg)
- Creatinine clearance less than 20 ml/min or creatinine greater than 2.5 mg/dl.
- Serum sodium less than 128 meq/L.
- Serum Potassium < 3.0 meq/L.
- Known adverse reaction to metolazone
- Inability to take oral medications
- Severe Aortic Stenosis (AVA < 0.8cm2)
- History of Hypertrophic obstructive cardiomyopathy
- Metastatic Carcinoma per history
- Severe COPD, FEV < 1L
- Severe dyspnea requiring prolonged CPAP,BIPAP or intubation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Experimental: Placebo
This group will receive all standard heart failure therapy and placebo pill.
|
All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician.
After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm.
The first placebo dose is given within six hours of admininstration of first dose of intravenous diuretic.
The second placebo dose is given at 24-hours after the first dose.
|
Active Comparator: Experimental: Metolazone
This group will receive all standard heart failure therapy with addition of metolazone.
|
All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician.
After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm.
The first dose of metolazone is given within six hours of admininstration of first dose of intravenous diuretic The second dose of metolazone is given 24-hours after the first dose.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total Urinary Output at 48 Hours
Time Frame: 48 hours
|
Total urinary output in milliliters (ml) at 48 hours.
Measurement timing began with administration of first dose of investigational product, ended 48 hours later.
|
48 hours
|
Fluid Balance at 48 Hours
Time Frame: 48 hours
|
Difference in value between input and output in milliliters (ml) at 48 hours.
Measurement timing began with administration of first dose of investigational product, ended 48 hours later.
Fluid balance = Fluid in minus Fluid out.
|
48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Weight First 48 Hours
Time Frame: 48 hours
|
Change in weight from the date/time of study enrollment (baseline) and 48 hours.
|
48 hours
|
Degree of Improvement in Dyspnea at 6, 12, 24, 36 and 48 Hours.
Time Frame: 6, 12, 24, 36 and 48 hours.
|
Dyspnea assessed at 6, 12, 24, 36 and 48 hours with Modified Borg Scale (1-10).
Range is from 1 (very slight) to 10 (maximal) dyspnea.
|
6, 12, 24, 36 and 48 hours.
|
Total Dose Diuretics First 48 Hours
Time Frame: 48 hours
|
Total dosage loop diuretic in first 48 hours using conversion tool to calculate intravenous Lasix equivalence
|
48 hours
|
Number of Participants With Inotrope Administration During First 48 Hours
Time Frame: 48 hours
|
Number of Participants with Inotrope administration during first 48 hours following study enrollment.
|
48 hours
|
All Cause Mortality at 30 Days
Time Frame: 30 Days
|
All Cause Mortality at 30 Days
|
30 Days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Length of Hospital Stay
Time Frame: Inpatient Hospitalization
|
Length of hospital stay in days
|
Inpatient Hospitalization
|
All Cause Readmission Within 30 Days
Time Frame: 30 Days
|
All Cause Readmission Within 30 Days
|
30 Days
|
Heart Failure Readmission Within 30 Days
Time Frame: 30 Days
|
Heart Failure Readmission Within 30 Days
|
30 Days
|
Number of Participants With Potassium Electrolyte Abnormality Requiring Replacement
Time Frame: 48 Hours
|
Severe electrolyte abnormalities requiring aggressive replacement defined as potassium levels less than 3.0 meq/L during the study.
|
48 Hours
|
Number of Participants With Magnesium Electrolyte Abnormality Requiring Replacement
Time Frame: 48 Hours
|
Number of Participants with severe electrolyte abnormalities requiring aggressive replacement defined as magnesium levels less than 1.5 meq/L during the study.
|
48 Hours
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Muhammad Chaudhry, MD, Aultman Health Foundation
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015.03.26.F2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Decompensated Heart Failure
-
Medical University of WarsawMedical University of Graz; Medical University of Vienna; Poznan University of... and other collaboratorsRecruitingAcute Decompensated Heart FailurePoland
-
Yooyoung Pharmaceutical Co., Ltd.RecruitingAcute Decompensated Heart FailureKorea, Republic of
-
Cardionomic Inc.Completed
-
Scripps HealthWithdrawnAcute Decompensated Heart FailureUnited States
-
Christian SchulzeBoehringer Ingelheim; Zentrum für Klinische Studien JenaCompletedAcute Decompensated Heart FailureGermany
-
Wake Forest University Health SciencesNational Institute on Aging (NIA)CompletedAcute Decompensated Heart FailureUnited States
-
Prof. Dr. Jörg LeuppiCompletedAcute Decompensated Heart FailureSwitzerland
-
Byung-Hee OhNational Institute of Health, KoreaCompletedAcute Decompensated Heart FailureKorea, Republic of
-
Trevena Inc.CompletedAcute Decompensated Heart FailureUnited States, Bulgaria, Poland, Russian Federation, Germany, Romania, Argentina, Canada, Czechia, Hungary, Israel, Slovakia
-
University of North Carolina, Chapel HillUniversity of Illinois at Chicago; Virginia Commonwealth UniversityTerminatedAcute Decompensated Heart FailureUnited States
Clinical Trials on Experimental: Placebo
-
Universidade Federal do CearáUnknown
-
Almirall, S.A.Completed
-
AstraZenecaCompleted
-
Hoffmann-La RocheErgomed GmbHCompletedDiabetic NeuropathyCroatia, Germany, Latvia, Poland, Serbia
-
Novartis PharmaceuticalsRecruitingResistant HypertensionChina, Italy, Spain, France, Netherlands, Taiwan, Germany, Czechia, Australia, Japan, United States, Bulgaria, United Kingdom, Poland, Austria, Slovakia
-
Medesis Pharma SATerminated
-
University of Las Palmas de Gran CanariaCompletedPostoperative Pain | ThoracicSpain
-
AstraZenecaCompletedUncontrolled AsthmaUnited States, Canada, Italy, United Kingdom, Philippines, Japan, Russian Federation, South Africa, Taiwan, Czechia, Mexico, Ukraine, Chile
-
Ono Pharma USA IncCompletedMajor Depressive DisorderUnited States
-
The Hospital for Sick ChildrenTerminated